By Daniella Parra
ProSomnus, Inc. (NASDAQ: OSA) announced a study that demonstrated that its oral treatment devices are an effective and safe alternative to CPAP for moderate and severe obstructive sleep apnea.
The company presented its research findings at the 2023 American Academy of Dental Sleep Medicine Annual Meeting and the American Thoracic Society 2023 International Conference, it said in a statement.
“Precision oral appliance therapy consists of intraoral medical devices that precisely track to the healthcare provider’s treatment plan and the patient’s anatomy,” said Len Liptak, Chief Executive Officer of ProSomnus. “This data further validates that our non-invasive, patient-preferred, precision oral appliance therapy is associated with excellent outcomes for patients with OSA.”
Contact:
Editor@Executives-edge.com
